Mateon Therapeutics (MATN) Enrolls First Patient in CA4P Phase 2/3 as Platinum-Resistant Ovarian Cancer Treatment
Tweet Send to a Friend
Mateon Therapeutics, Inc. (Nasdaq: MATN) announced that it has enrolled the first patient into its FOCUS Study, a phase 2/3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
